Japan Tissue Engineering Co (TSE:7774) EBIT: 円-549 Mil (TTM As of Mar. 2026)


TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
60 GF Score
Price 円630.00
GF Value 円517.18
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co EBIT?

Japan Tissue Engineering Co TSE:7774 -0.32% 60 EBIT is 円-549 Mil as of Mar. 2026. GuruFocus rates TSE:7774 with a GF Score™ of 60/100 and a GF Value™ of 円517.18 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Japan Tissue Engineering Co's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was 円-173 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円-549 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Japan Tissue Engineering Co's annualized ROC % for the quarter that ended in Mar. 2026 was -15.25%. Japan Tissue Engineering Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -21.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Japan Tissue Engineering Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -2.46%.

Japan Tissue Engineering Co  (TSE:7774) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Japan Tissue Engineering Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-346.694 * ( 1 - 0% )/( (2331.174 + 2214.527)/ 2 )
=-346.694/2272.8505
=-15.25 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6102.222 - 42.354 - ( 3728.694 - max(0, 616.337 - 4469.456+3728.694))
=2331.174

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5682.993 - 218.001 - ( 3250.465 - max(0, 560.509 - 4182.077+3250.465))
=2214.527

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Japan Tissue Engineering Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-346.694/( ( (1376.729 + max(124.425, 0)) + (1336.84 + max(371.103, 0)) )/ 2 )
=-346.694/( ( 1501.154 + 1707.943 )/ 2 )
=-346.694/1604.5485
=-21.61 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(354.158 + 208.236 + 178.368) - (42.354 + 0 + 573.983)
=124.425

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(512.669 + 235.197 + 183.746) - (218.001 + 0 + 342.508)
=371.103

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Japan Tissue Engineering Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-549.44/22333.804
=-2.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co EBIT Related Terms

Japan Tissue Engineering Co EBIT Historical Data

* Premium members only.

The historical data trend for Japan Tissue Engineering Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co EBIT Chart

Japan Tissue Engineering Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -498.18 -728.12 144.51 -238.31 -549.44

Japan Tissue Engineering Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 155.37 -207.33 -30.98 -376.09 -173.35

TSE:7774 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Japan Tissue Engineering Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Japan Tissue Engineering Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Japan Tissue Engineering Co's EV-to-EBIT falls into.


TSE:7774
60GF Score
Japan Tissue Engineering Co Ltd TSE:7774
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Japan Tissue Engineering Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円-549 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円-549 Mil mean?
Japan Tissue Engineering Co (TSE:7774) has a EBIT of 円-549 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Japan Tissue Engineering Co.
Is Japan Tissue Engineering Co's EBIT too high?
Japan Tissue Engineering Co's current EBIT is 円-549 Mil. Overall, Japan Tissue Engineering Co has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's EBIT compare to VRTX and REGN?
Japan Tissue Engineering Co's EBIT of 円-549 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Japan Tissue Engineering Co. Japan Tissue Engineering Co's current EBIT is 円-549 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.18, compared to a current price of 円630.00 — trading 21.8% above its estimated fair value. The current EBIT is 円-549 Mil. Japan Tissue Engineering Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current EBIT is 円-549 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円630.00 is trading 21.8% above its estimated GF Value™ of 円517.18. GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.

Key valuation signals for TSE:7774:

  • EBIT: 円-549 Mil
  • GF Value™: 円517.18 vs. price of 円630.00 (21.8% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
60GF Score

Get the complete analysis for TSE:7774

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円630.00
Price
円517.18
GF Value